Cargando…
Ischaemia-free liver transplantation in humans: a first-in-human trial
Background Ischaemia-reperfusion injury is considered an inevitable component of organ transplantation, compromising organ quality and outcomes. Although several treatments have been proposed, none has avoided graft ischaemia and its detrimental consequences. Methods Ischaemia-free liver transplanta...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406025/ https://www.ncbi.nlm.nih.gov/pubmed/34590063 http://dx.doi.org/10.1016/j.lanwpc.2021.100260 |
_version_ | 1783746439054098432 |
---|---|
author | Guo, Zhiyong Zhao, Qiang Huang, Shanzhou Huang, Changjun Wang, Dongping Yang, Lu Zhang, Jian Chen, Maogen Wu, Linwei Zhang, Zhiheng Zhu, Zebin Wang, Linhe Zhu, Caihui Zhang, Yixi Tang, Yunhua Sun, Chengjun Xiong, Wei Shen, Yuekun Chen, Xiaoxiang Xu, Jinghong Wang, Tielong Ma, Yi Hu, Anbin Chen, Yinghua Zhu, Xiaofeng Rong, Jian Cai, Changjie Gong, Fengqiu Guan, Xiangdong Huang, Wenqi Ko, Dicken Shiu-Chung Li, Xianchang Tullius, Stefan G Huang, Jiefu Ju, Weiqiang He, Xiaoshun |
author_facet | Guo, Zhiyong Zhao, Qiang Huang, Shanzhou Huang, Changjun Wang, Dongping Yang, Lu Zhang, Jian Chen, Maogen Wu, Linwei Zhang, Zhiheng Zhu, Zebin Wang, Linhe Zhu, Caihui Zhang, Yixi Tang, Yunhua Sun, Chengjun Xiong, Wei Shen, Yuekun Chen, Xiaoxiang Xu, Jinghong Wang, Tielong Ma, Yi Hu, Anbin Chen, Yinghua Zhu, Xiaofeng Rong, Jian Cai, Changjie Gong, Fengqiu Guan, Xiangdong Huang, Wenqi Ko, Dicken Shiu-Chung Li, Xianchang Tullius, Stefan G Huang, Jiefu Ju, Weiqiang He, Xiaoshun |
author_sort | Guo, Zhiyong |
collection | PubMed |
description | Background Ischaemia-reperfusion injury is considered an inevitable component of organ transplantation, compromising organ quality and outcomes. Although several treatments have been proposed, none has avoided graft ischaemia and its detrimental consequences. Methods Ischaemia-free liver transplantation (IFLT) comprises surgical techniques enabling continuous oxygenated blood supply to the liver of brain-dead donor during procurement, preservation, and implantation using normothermic machine perfusion technology. In this non-randomised study, 38 donor livers were transplanted using IFLT and compared to 130 conventional liver transplants (CLT). Findings Two recipients (5•3%) in the IFLT group experienced early allograft dysfunction, compared to 50•0% in patients receiving conventional transplants (absolute risk difference, 44•8%; 95% confidence interval, 33•6-55•9%). Recipients of IFLT had significantly reduced median (IQR) peak aspartate aminotransferase levels within the first week compared to CLT recipients (365, 238-697 vs 1445, 791-3244 U/L, p<0•001); likewise, median total bilirubin levels on day 7 were significantly lower (2•34, 1•39-4•09 mg/dL) in the IFLT group than in the CLT group (5•10, 1•90-11•65 mg/dL) (p<0•001). Moreover, IFLT recipients had a shorter median intensive care unit stay (1•48, 0•75-2•00 vs 1•81, 1•00-4•58 days, p=0•006). Both one-month recipient (97•4% vs 90•8%, p=0•302) and graft survival (97.4% vs 90•0%, p=0•195) were better for IFLT than CLT, albeit differences were not statistically significant. Subgroup analysis showed that the extended criteria donor livers transplanted using the IFLT technique yielded faster post-transplant recovery than did the standard criteria donor livers transplanted using the conventional approach. Interpretation IFLT provides a novel approach that may improve outcomes, and allow the successful utilisation of extended criteria livers. Funding This study was funded by National Natural Science Foundation of China, Guangdong Provincial Key Laboratory Construction Projection on Organ Donation and Transplant Immunology, and Guangdong Provincial international Cooperation Base of Science and Technology. Panel: Research in context |
format | Online Article Text |
id | pubmed-8406025 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-84060252021-09-28 Ischaemia-free liver transplantation in humans: a first-in-human trial Guo, Zhiyong Zhao, Qiang Huang, Shanzhou Huang, Changjun Wang, Dongping Yang, Lu Zhang, Jian Chen, Maogen Wu, Linwei Zhang, Zhiheng Zhu, Zebin Wang, Linhe Zhu, Caihui Zhang, Yixi Tang, Yunhua Sun, Chengjun Xiong, Wei Shen, Yuekun Chen, Xiaoxiang Xu, Jinghong Wang, Tielong Ma, Yi Hu, Anbin Chen, Yinghua Zhu, Xiaofeng Rong, Jian Cai, Changjie Gong, Fengqiu Guan, Xiangdong Huang, Wenqi Ko, Dicken Shiu-Chung Li, Xianchang Tullius, Stefan G Huang, Jiefu Ju, Weiqiang He, Xiaoshun Lancet Reg Health West Pac Research Paper Background Ischaemia-reperfusion injury is considered an inevitable component of organ transplantation, compromising organ quality and outcomes. Although several treatments have been proposed, none has avoided graft ischaemia and its detrimental consequences. Methods Ischaemia-free liver transplantation (IFLT) comprises surgical techniques enabling continuous oxygenated blood supply to the liver of brain-dead donor during procurement, preservation, and implantation using normothermic machine perfusion technology. In this non-randomised study, 38 donor livers were transplanted using IFLT and compared to 130 conventional liver transplants (CLT). Findings Two recipients (5•3%) in the IFLT group experienced early allograft dysfunction, compared to 50•0% in patients receiving conventional transplants (absolute risk difference, 44•8%; 95% confidence interval, 33•6-55•9%). Recipients of IFLT had significantly reduced median (IQR) peak aspartate aminotransferase levels within the first week compared to CLT recipients (365, 238-697 vs 1445, 791-3244 U/L, p<0•001); likewise, median total bilirubin levels on day 7 were significantly lower (2•34, 1•39-4•09 mg/dL) in the IFLT group than in the CLT group (5•10, 1•90-11•65 mg/dL) (p<0•001). Moreover, IFLT recipients had a shorter median intensive care unit stay (1•48, 0•75-2•00 vs 1•81, 1•00-4•58 days, p=0•006). Both one-month recipient (97•4% vs 90•8%, p=0•302) and graft survival (97.4% vs 90•0%, p=0•195) were better for IFLT than CLT, albeit differences were not statistically significant. Subgroup analysis showed that the extended criteria donor livers transplanted using the IFLT technique yielded faster post-transplant recovery than did the standard criteria donor livers transplanted using the conventional approach. Interpretation IFLT provides a novel approach that may improve outcomes, and allow the successful utilisation of extended criteria livers. Funding This study was funded by National Natural Science Foundation of China, Guangdong Provincial Key Laboratory Construction Projection on Organ Donation and Transplant Immunology, and Guangdong Provincial international Cooperation Base of Science and Technology. Panel: Research in context Elsevier 2021-08-26 /pmc/articles/PMC8406025/ /pubmed/34590063 http://dx.doi.org/10.1016/j.lanwpc.2021.100260 Text en © 2021 The Author(s). Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Guo, Zhiyong Zhao, Qiang Huang, Shanzhou Huang, Changjun Wang, Dongping Yang, Lu Zhang, Jian Chen, Maogen Wu, Linwei Zhang, Zhiheng Zhu, Zebin Wang, Linhe Zhu, Caihui Zhang, Yixi Tang, Yunhua Sun, Chengjun Xiong, Wei Shen, Yuekun Chen, Xiaoxiang Xu, Jinghong Wang, Tielong Ma, Yi Hu, Anbin Chen, Yinghua Zhu, Xiaofeng Rong, Jian Cai, Changjie Gong, Fengqiu Guan, Xiangdong Huang, Wenqi Ko, Dicken Shiu-Chung Li, Xianchang Tullius, Stefan G Huang, Jiefu Ju, Weiqiang He, Xiaoshun Ischaemia-free liver transplantation in humans: a first-in-human trial |
title | Ischaemia-free liver transplantation in humans: a first-in-human trial |
title_full | Ischaemia-free liver transplantation in humans: a first-in-human trial |
title_fullStr | Ischaemia-free liver transplantation in humans: a first-in-human trial |
title_full_unstemmed | Ischaemia-free liver transplantation in humans: a first-in-human trial |
title_short | Ischaemia-free liver transplantation in humans: a first-in-human trial |
title_sort | ischaemia-free liver transplantation in humans: a first-in-human trial |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406025/ https://www.ncbi.nlm.nih.gov/pubmed/34590063 http://dx.doi.org/10.1016/j.lanwpc.2021.100260 |
work_keys_str_mv | AT guozhiyong ischaemiafreelivertransplantationinhumansafirstinhumantrial AT zhaoqiang ischaemiafreelivertransplantationinhumansafirstinhumantrial AT huangshanzhou ischaemiafreelivertransplantationinhumansafirstinhumantrial AT huangchangjun ischaemiafreelivertransplantationinhumansafirstinhumantrial AT wangdongping ischaemiafreelivertransplantationinhumansafirstinhumantrial AT yanglu ischaemiafreelivertransplantationinhumansafirstinhumantrial AT zhangjian ischaemiafreelivertransplantationinhumansafirstinhumantrial AT chenmaogen ischaemiafreelivertransplantationinhumansafirstinhumantrial AT wulinwei ischaemiafreelivertransplantationinhumansafirstinhumantrial AT zhangzhiheng ischaemiafreelivertransplantationinhumansafirstinhumantrial AT zhuzebin ischaemiafreelivertransplantationinhumansafirstinhumantrial AT wanglinhe ischaemiafreelivertransplantationinhumansafirstinhumantrial AT zhucaihui ischaemiafreelivertransplantationinhumansafirstinhumantrial AT zhangyixi ischaemiafreelivertransplantationinhumansafirstinhumantrial AT tangyunhua ischaemiafreelivertransplantationinhumansafirstinhumantrial AT sunchengjun ischaemiafreelivertransplantationinhumansafirstinhumantrial AT xiongwei ischaemiafreelivertransplantationinhumansafirstinhumantrial AT shenyuekun ischaemiafreelivertransplantationinhumansafirstinhumantrial AT chenxiaoxiang ischaemiafreelivertransplantationinhumansafirstinhumantrial AT xujinghong ischaemiafreelivertransplantationinhumansafirstinhumantrial AT wangtielong ischaemiafreelivertransplantationinhumansafirstinhumantrial AT mayi ischaemiafreelivertransplantationinhumansafirstinhumantrial AT huanbin ischaemiafreelivertransplantationinhumansafirstinhumantrial AT chenyinghua ischaemiafreelivertransplantationinhumansafirstinhumantrial AT zhuxiaofeng ischaemiafreelivertransplantationinhumansafirstinhumantrial AT rongjian ischaemiafreelivertransplantationinhumansafirstinhumantrial AT caichangjie ischaemiafreelivertransplantationinhumansafirstinhumantrial AT gongfengqiu ischaemiafreelivertransplantationinhumansafirstinhumantrial AT guanxiangdong ischaemiafreelivertransplantationinhumansafirstinhumantrial AT huangwenqi ischaemiafreelivertransplantationinhumansafirstinhumantrial AT kodickenshiuchung ischaemiafreelivertransplantationinhumansafirstinhumantrial AT lixianchang ischaemiafreelivertransplantationinhumansafirstinhumantrial AT tulliusstefang ischaemiafreelivertransplantationinhumansafirstinhumantrial AT huangjiefu ischaemiafreelivertransplantationinhumansafirstinhumantrial AT juweiqiang ischaemiafreelivertransplantationinhumansafirstinhumantrial AT hexiaoshun ischaemiafreelivertransplantationinhumansafirstinhumantrial |